Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.Learn More
Our pipeline currently includes nine product candidates being developed by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.
Our lead drug candidate, Entolimod (CBLB502), is being developed for dual indications as a radiation countermeasure through the FDA’s Animal Efficacy Rule and as a targeted cancer therapy and supportive care agent through the FDA’s traditional drug approval pathway.
We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.
Enrollment is open for our therapeutic clinical trials for various indications with oncology and orphan drug candidates in the pipeline.